During the past decade, JOHAS Tohoku Rosai Hospital conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 5 clinical trials were completed, i.e. on average, 55.6% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 5 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "JOHAS Tohoku Rosai Hospital" #1 sponsor was "Shire" with 3 trials, followed by "Arena Pharmaceuticals" with 2 trials sponsored, "Pfizer" with 2 trials sponsored, "Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan" with 2 trials sponsored and "Gilead Sciences" with 2 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "JOHAS Tohoku Rosai Hospital" #1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 2 trials as a collaborator, "Tokyo Medical and Dental University" with 2 trials as a collaborator and "Korean Cancer Study Group" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "JOHAS Tohoku Rosai Hospital" are "Ulcerative Colitis" (7 trials), "Colorectal Cancer" (2 trials), "Complex Perianal Fistulas in Adult Participants With Crohn's Disease" (1 trials), "Crohn's Disease" (1 trials) and "Gastric Cancer" (1 trials). Many other conditions were trialed in "JOHAS Tohoku Rosai Hospital" in a lesser frequency.

Most popular intervention types in "JOHAS Tohoku Rosai Hospital" are "Drug" (11 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Etrasimod" (4 trials), "Ontamalimab" (2 trials), "UFT adjuvant chemotherapy" (2 trials) and "25 mg Ontamalimab" (1 trials). Other intervention names were less common.

The vast majority of trials in "JOHAS Tohoku Rosai Hospital" are 12 trials for "All" genders.

Currently, there are NaN active trials in "JOHAS Tohoku Rosai Hospital". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in JOHAS Tohoku Rosai Hospital, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in JOHAS Tohoku Rosai Hospital, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".